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Abstract: Four new 8-hydroxybriarane diterpenoids, frajunolides L–O (1–4), were isolated 
from the Taiwanese gorgonian Junceella fragilis. The structures of compounds 1–4 were 
elucidated based on spectroscopic analysis, especially 2D NMR (
1H-
1H COSY, HSQC, 
HMBC and NOESY) and HRMS. Compounds 1 and 4 showed weak anti-inflammatory 
activity as tested by superoxide anion generation and elastase release by human neutrophil 
in response to fMLP/CB. Compound 3 showed selective inhibition on elastase release 
in vitro. 
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1. Introduction 
A number of secondary metabolites with potential pharmacological activities such as cytotoxic, 
antiviral, anti-inflammatory, and insecticidal effects were discovered from marine organisms [1]. 
Marine diterpenoids of the class briarane have been investigated with great interest owing to their 
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novel structures and interesting bioactivities [2–5]. The gorgonian of the genus Junceella grown in the 
tropical and subtropical waters of Indo-West Pacific regions are well known as a source of highly 
oxidized briarane-type diterpenoids with a γ-lactone moiety [6–9]. In continuation of our study on the 
chemistry and biological activities of briarane diterpenoids [10–16], we investigated the Taiwanese 
gorgonian  J. fragilis. A chemical investigation of the acetone extract has yielded four new   
8-hydroxybriarane diterpenoids, designated as frajunolides L–O (1–4). In this paper, we report the 
isolation, structural elucidation, and anti-inflammatory activity as tested by superoxide anion 
generation and elastase release by human neutrophil in response to fMLP/CB, of these compounds. 
Chart 1. Structures of Frajunolides L–O (1–4). 
O
O
AcO
OH
AcO
OAc
AcO
2
O
O
AcO
OH
AcO
AcO
OAc
Cl
4
O
O
AcO
OH
AcO
OAc
O
Cl
OAc
3
O
O
AcO
OH
AcO
AcO
OAc
1
1
2
5
6
7 9
10
11
12
13
14
15
16
17
18
19
20
H
3
4
 
2. Results and Discussion  
Compound  1 was deduced to have the molecular formula C28H38O11 with ten degrees of 
unsaturation from high-resolution ESI mass spectrometry. The IR absorptions were observed at 3439, 
1768 and 1735 cm
−1 suggesting the presence of hydroxyl, γ-lactone and ester groups, respectively. The 
1H-, 
13C-NMR and DEPT spectroscopic data (Table 1) revealed that compound 1 possessed four acetyl 
groups (δH 1.94, 1.98, 2.13, and 2.21), two tertiary methyl protons (δH 1.15, Me-15; δH 2.03, Me-16), a 
doublet methyl (δH 1.15 , d, J = 6.9 Hz, Me-19), five oxygenated methine protons (δH 4.94, t, J = 3.3 Hz, 
H-2; δH 5.28, d, J = 9.6 Hz, H-7; δH 5.62, d, J = 5.1 Hz, H-9; δH 5.32, m, H-12; 4.77, br s, H-14), a 
trisubstituted olefinic group (δH 5.58, d, J = 9.6 Hz, H-6; δC 120.0, C-6; δC 145.2, C-5), an oxygenated 
quaternary carbon (δC 82.6, C-8), an exocyclic double bond (δH 5.34, 5.30, H2-20; δC 118.3, C-20; 
146.3, C-11), two methine carbons (δC 40.6, C-10; δC 43.2, C-17), three methylene carbons (δC 30.8, 
C-3; δC 29.0, C-4; δC 33.5, C-13), along with a γ-lactone carbonyl carbon (δC 175.9, C-18). The proton 
and carbon assignments of 1 were completely established by using 1D- and 2D NMR experiments, 
including 
1H-
1H COSY, HSQC, and HMBC (Figure 1). The 
1H-
1H COSY spectrum exhibited four sets 
of correlations (H-2/H-3/H-4, H-6/H-7, H-9/H-10, and H-12/H-13/H-14). The HMBC correlations of 
Me-15 (δH 1.15, s)/C-1 (δC 47.0), C-2 (δC 74.2), C-10 (δC 40.6), C-14 (δC 73.6); Me-16 (δH 2.03, s)/C-4 
(δC 29.0), C-5 (δC 145.2), C-6 (δC 120.0); Me-19 (δH 1.15, d,  J = 6.9 Hz)/C-8 (δC 82.6), C-18   
(δC 175.9); H-9 (δH 5.62, d, J = 5.1 Hz)/C-8, C-7 (δC 78.0); H-10 (δH 3.57, d, J = 5.1 Hz)/C-1, C-2, C-11 
(δC 146.3), C-12 (δC 71.5); H2-20 (δH 5.34, s; 5.30, s)/C-11, C-12; H-13 (δH 1.95, m; 2.20, m)/C-14,  
C-1 established the connectivities from C-1 to C-20 unambiguously, and revealed that compound 1 
belongs to 8-hydroxybriarane diterpenoids with a γ-lactone ring [11]. The four acetate groups of 1 
were assigned at C-2, C-9, C-12, and C-14 positions by the HMBC correlations between the acetate Mar. Drugs 2011, 9  
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carbonyl carbons (δC 170.4 × 2, 170.3, and 168.9) and four oxygenated methine protons (δH 4.94, H-2; 
δH 5.62, H-9; δH 5.32, H-12; 4.77, H-14). Thus the planar structure of 1 was completely established.  
Figure 1. 
1H-
1H COSY and HMBC correlations of 1; NOESY correlations and   
computer-generated perspective model of 1 using MM2 force field calculation. 
 
Our results showed that the planar structure of compound 1 is the same as frajunolide A, but 
differing in the 
1H- and 
13C NMR data of the methylenecyclohexane ring, especially at C-12 and C-20 
positions [10]. The 
13C NMR chemical shift of C-12 (δC 71.5) was shifted downfield in comparison 
with frajunolide A (δC 67.3), suggesting that the relative stereochemistry of H-12 was α-orientation [11]. 
The relative configuration of 1 was determined by NOESY correlations (Figure 1) and MM2 
minimized energy calculated molecular modeling, and comparison with other naturally occurring 
briarane diterpenoids [2–5]. Briarane-type diterpenoids were reported to have the Me-15 in the   
β-orientation and H-10 in the α-orientation. In the NOESY of 1, H-10 showed correlations with H-2, 
H-9, H-12, suggesting that these protons are located on the α-face. In addition, the correlation between 
H-9 and Me-19 indicated that Me-19 is α-oriented too. However, correlation of H-17/H-7 suggested 
that H-7 and H-17 are on the β-face. Moreover, NOESY correlation of H-14/Me-15 suggested that  
14-acetoxy group is located on the α-face. The Z-configuration at C-5 was elucidated by the 
observation of NOESY correlation between H-6 and Me-16. On the basis of the above interpretation, 
the structure of compound 1 was elucidated. The name frajunolide L was given. 
Compound  2 had the molecular formula C28H38O11, the same as that of 1, as determined by 
HRESIMS, suggesting that the structure of 2 was similar to 1. The IR spectrum of 2 also displayed 
strong absorptions at 3429, 1776 and 1735 cm
−1 indicating that compound 2 contained hydroxyl and 
carbonyl groups of five-membered γ-lactone ring and ester groups. Both 
1H- and 
13C NMR 
spectroscopic data (Table 1) of 2 were found to be similar to those of 1. These signals include four 
acetyl group (δH 1.92, 2.01, 2.07, and 2.16), two tertiary methyl protons (δH 0.99, Me-15; δH 1.99,  
Me-16), a methyl doublet (δH 1.17, d, J = 6.8 Hz, Me-19), and a methine quartet (δH 1.15, q, J = 7.2 Hz). 
However, 1D- and 2D-spectroscopic data of 2 revealed that the exocyclic double bond (C-11/C-20) in 
1 shifted to C-12 (δC 127.6)/C-11 (δC 134.2) and an acetate group was found to locate at C-20   
(δC 68.7). The gross structure of 2 was further deduced from the 
1H-
1H COSY, HMQC, HMBC 
correlations (Figure 2). The relative configuration of 2 was determined by NOESY correlations (Figure 2) Mar. Drugs 2011, 9  
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and application of MM2 molecular modeling together with comparing the NMR spectra of 2 with 
those of 1. The NOESY correlations of H-10/H-2, H-9, and H-9/Me-19 suggested that the 
configurations of H-2, H-9, H-10, and Me-19 were in α-orientation while correlations of H-7/H-6,  
H-17, and H-14/Me-15 agreed with β-disposition of H-7, H-14, Me-15 and H-17.  
Table 1. NMR spectroscopic data for compounds 1–4. 
 1  
b 2  
b 3  
c 4  
c 
Position  δH (J in Hz) 
a  δH, mult. 
d  δH (J in Hz)  δH, mult. δH (J in Hz)  δH, mult.  δH (J in Hz)  δH, mult. 
1    47.0, C     45.7, C     48.9, C     48.3, C  
2  4.94, t (3.3)  74.2, CH   5.01, m  75.0, CH  6.68, d (8.5)  73.2, CH   6.62, d (8.0)  74.8, CH  
3  2.16, m  30.8, CH2   2.54, m  33.3, CH2 3.58, dd (16.0, 10.5) 37.3, CH2   2.88, m  29.3, CH2 
  1.72, m    1.61, m    2.03, dd (16.0, 8.5)   1.70, m   
4  2.58, m  29.0, CH2   1.95, m  29.7, CH2 5.90, d (10.5)  77.6, CH   2.52, m  33.4, CH2 
 2.08,  m              
5    145.2, C     146.1, C    144.0, C     144.9, C  
6  5.58, d (9.6)  120.0, CH   5.41, d (9.2)  117.7, CH 5.42, d (3.5)  54.2, CH   5.21, d (3.2)  56.2, CH  
7  5.28, d (9.6)  78.0, CH   5.32, d (9.2)  79.1, CH  4.94, d (3.5)  85.3, CH   4.92, m  84.9, CH  
8    82.6, C    82.5, C     82.7, C     82.1, C  
9  5.62, d (5.1)  72.6, CH   5.74, s  71.4, CH  6.30, s  72.6, CH   6.28, s  79.3, CH  
10  3.57, d (5.1)  40.6, CH   3.07, s  39.9, CH  3.62, s  42.4, CH   3.82, s  44.6, CH  
11    146.3, C     134.2, C    58.2, C     147.0, C  
12  5.32, m  71.5, CH   5.85 br, s  127.6, CH 2.27, m  31.6, CH2   2.63, t (12.4)  38.6, CH2 
          1.28, m    2.49, m   
13  2.20, m  33.5, CH2   2.28, m  28.1, CH2 1.94, m  25.5, CH2   5.27, ddd (3.2, 5.2, 12.0) 70.1, CH  
  1.95, m    2.11, m           
14  4.77 br, s  73.6, CH  4.75 br, s  73.7, CH  5.25, s   75.2, CH   5.66, s  73.8, CH  
15  1.15, s  15.4, CH3  0.99, s  16.2, CH3 1.31, s  15.2, CH3   1.27, s  14.4, CH3 
16  2.03, s  27.0, CH3   1.99, s  29.0, CH3 5.83, s  125.5, CH2  4.92, s  118.3, CH2 
          5.42, s    5.49, s   
17  2.54, q (6.9)  43.2, CH   2.45, q (7.2)  44.7, CH 3.44, q (7.0)  51.8, CH   3.41, q (7.6)  51.4, CH  
18    175.9, C     174.7, C    176.4, C    175.8, C  
19  1.15, d (6.9)  6.7, CH3  1.17, d (6.8)  8.7, CH3 1.41, d (7.0)  7.3, CH3  1.26, d (7.6)  6.7, CH3  
20  5.34, s  118.3, CH2 4.67, d (12.0) 68.7, CH2 2.84, d (4.0)  52.6, CH2   4.92, s  113.1, C  
  5.30, s    5.02, d (12.0)    2.59 br, s    5.19, s   
OAc  2.21, s  170.4, C   2.16, s  169.9, C  2.30, s  172.5, C   2.28, s  171.8, C  
  2.13, s  170.4, C   2.07, s  169.7, C  2.30, s  171.1, C   2.09, s  170.9, C  
  1.98, s  170.3, C   2.01, s  169.3, C  2.11, s  171.1, C   2.07, s  170.8, C  
  1.94, s  168.9, C   1.92, s  168.4, C  1.99, s  170.3, C   1.99, s  170.3, C  
   21.7,  CH3     23.1, CH3  22.2,  CH3     21.9, CH3 
   21.2,  CH3     22.9, CH3  21.9,  CH3     21.1, CH3 
   21.2,  CH3     22.8, CH3  21.8,  CH3     21.0, CH3 
   21.1,  CH3     22.7, CH3  21.5,  CH3     20.9, CH3 
8-OH              8.05 br, s   
a Data were recorded at 400 and/or 500 MHz in CDCl3; 
b In CDCl3; 
c In pyridine-d5; 
d Data recorded at 100 and/or 125 MHz 
and were assigned by DEPT, COSY, HSQC, and HMBC experiments. 
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Figure 2. 
1H-
1H COSY and HMBC correlations of 2; NOESY correlations and   
computer-generated perspective model of 2 using MM2 force field calculation. 
 
The HRESI mass spectrum of 3 gave a quasi-molecular ion peak at m/z 589.2266 [M + Na]
+, 
indicative of a molecular formula C28H38ClO12 (calc. for m/z 589.2261), consistent with 10 degrees of 
unsaturation. The presence of a chloride was evident from the fragment [M + Na]
+ at m/z 589 and the 
isotope fragment [M + Na + 2]
+ at m/z 591 in ESIMS, with the typical ratio of relative intensity (3:1) 
in the mass spectrum. In the infrared spectrum, strong absorption bands were found at 3436, 1735 and 
1780 cm
−1 characteristic for hydroxyl, ester carbonyl (acetyl) and five-membered γ-lactone ring, 
suggesting a briarane-type diterpenoid similar to compounds 1 and 2. It was found that the 
1H- and 
13C 
NMR spectra of 3 in CDCl3 showed mostly broad peaks and in some cases, certain peaks were not 
observed. In order to mark more optimum signals of the NMR spectra, compound 3 was dissolved in 
pyridine-d5. The 
1H- and 
13C NMR data (Table 1) of 3 revealed the presence of four acetate groups  
(δH 1.99, 2.11, and 2.30 × 2; δC 172.5, 171.1 × 2, 170.3, 22.2, 21.9, 21.8, and 21.5), an exocyclic 
double bond (δH 5.83, 5.42, H2-16;  δC 144.0, C-5; 125.5, C-16) and a γ-lactone carbonyl carbon   
(δC 176.4, C-19). Judging from the molecular formula and NMR data of 3, six degrees of unsaturation 
were counted for, indicating that compound 3 contained a tetracyclic system including an exocyclic 
epoxide (δH 2.84, d, J = 4.0 Hz; 2.59, br s, H2-20; δC 58.2, C-11; 52.6, C-20). The HMBC correlations 
(Figure 3) between H-2 (δH 6.68, d, J = 8.5 Hz), H-4 (δH 5.90, d, J = 10.5 Hz), H-9 (δH 6.30, s), and  
H-14 (δH 5.25, s) with one of ester carbonyl carbons, respectively, revealed that four acetyl groups 
were connected to the C-2, C-4, C-9, and C-14 positions. By interpretation of the NMR spectroscopic 
data, the planar structure of compound 3 was elucidated. The relative configuration of 3 was 
determined by NOESY (Figure 3) and detailed comparison with known compounds [10]. The chemical 
shift of C-11 (δC 58.2) and C-20 (δC 52.6), and the NOESY correlations between H2-20 and Me-15 
agreed with β-face of H2-20, 11R-configuration regarding the exocyclic epoxide, and chair 
conformation of the cyclohexane ring. Furthermore, NOESY correlations of H-10/H-2, H-4/H-2 and 
H-10/H-9 suggested that H-2, H-4 and H-9 were located on the same face and could be assigned as α. 
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Figure 3. 
1H-
1H COSY, HMBC, and NOESY correlations of 3. 
 
Compound 4 showed a pair of quasi-molecular ion peaks at m/z 607 and 609 [M + H]
+ with a ratio 
of 3:1 in the ESIMS, indicating the presence of a chlorine atom. Moreover, a molecular formula 
C28H37ClO11 was established by HRESIMS and confirmed by 
1H- and 
13C NMR spectroscopic analysis 
(Table 1). The IR absorption bands at 3467, 1780 and 1739 cm
−1 indicated that 4 contained hydroxyl, 
γ-lactone, and ester carbonyl functionalities similar to 1–3. Detailed inspection of 
1H- and 
13C NMR 
spectroscopic data revealed the presence of the key structural feature of a 8-hydroxybriarane 
diterpenoid with two exocyclic double bonds. The locations of the two exocyclic double bonds were 
confirmed by the HMBC experiment (Figure 4), which showed correlations of H2-16 (δH 4.92, s;  
5.49, s)/C-4 (δC 33.4), C-5 (δC 144.9), and C-6 (δC 56.2), and H2-20 (δH 4.92, s; 5.19, s)/C-10 (δC 44.6), 
C-11 (δC 147.0), and C-12 (δC 38.6), respectively. In addition, the oxygenated methine proton H-2  
(δH 6.62, d, J = 8.0 Hz), H-9 (δH 6.28,), H-13 (δH 5.72, ddd, J = 12.0, 5.2, 3.2 Hz), and H-14 (δH 5.66, s) 
showed HMBC correlations with the acetate carbonyl carbons (δC 171.8, 170.9, 170.8, 170.3). 
Furthermore, detailed analysis of 2D NMR spectroscopic data (
1H-
1H COSY and HMBC) established 
the planar structure of 4. The configuration of compound 4 was determined on the basis of NOESY 
correlations (Figure 4). The NOESY correlations of Me-15 (δH 1.27, s)/H-14 and H-13/H-14 implied 
that H-13 and H-14 are on the β-face while correlations of H-2/H-10, H-10/H-9, H-9/Me-19, H-17/H-7 
and H-6/H-7 confirmed that the configuration of these protons are identical to those of compound 3. 
Figure 4. 
1H-
1H COSY, HMBC, and NOESY correlations of 4. 
 
General pharmacological study of the anti-inflammatory activities of compounds 1–4 were 
evaluated by measuring superoxide anion generation and elastase release by human neutrophils in 
response to fMet-Leu-Phe (fMLP)/Cytochalasin B (CB) [17]. The results are illustrated in Table 2. Mar. Drugs 2011, 9  
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Compounds 1 and 4 showed mild inhibitory effects on both superoxide anion generation and elastase 
release at 10 μg/mL. It is notable that compound 3 exhibited selective but modest inhibition of elastase 
release in vitro. 
Table 2. Effects of compounds on superoxide anion generation and elastase release by 
human neutrophils in response to fMet-Leu-Phe (fMLP)/Cytochalasin B (CB). 
Compounds 
Superoxide anion  Elastase release 
Inh % 
a Inh  % 
a 
1  18.7 ± 2.6 **  16.2 ± 0.7 *** 
2  2.0 ± 2.3  13.3 ± 3.1 * 
3  0.6 ± 1.5  22.3 ± 7.7 
4  8.3 ± 3.6  17.2 ± 6.7 * 
Genistein  65.0 ± 5.7  51.6 ± 5.9 
a Percentage of inhibition Inh % at 10 μg/mL concentration. Results are presented as   
mean ± S.E.M. (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 compared with the control value. 
3. Experimental Section  
3.1. General Experimental Procedures  
Optical rotations were recorded on a JASCO DIP-1000 polarimeter. IR spectra were measured on a 
Hitachi T-2001 spectrophotometer. The 
1H-
13C NMR, COSY, HMQC, HMBC, and NOESY spectra 
were recorded on a Bruker AV-400 or a AV-500 spectrometer, using TMS as internal standard. The 
chemical shifts are given in δ (ppm) and coupling constants (J) in Hz. HRESIMS were run on a JEOL 
JMS-HX 110 mass spectrometer. Silica gel 60 (Merck) was utilized for column chromatography, and 
precoated silica gel plates (Merck, Kieselgel 60 F-254, 1 mm) were used in preparative TLC. 
Sephadex LH-20 (Amersham Pharmacia Biotech AB, Sweden) was used for separation and 
purification of compounds. LiChrospher Si 60 (5 μm, 250-10, Merck) and LiChrospher 100 RP-18e  
(5 μm, 250-10, Merck) were used in NP-HPLC and RP-HPLC (Hitachi), respectively. 
3.2. Animal Material 
The gorgonian Junceella fragilis Ridley (Ellisellidae) was collected in Tai-Tong County, Taiwan, 
by scuba diving at a depth of 15 meters, in February 2006. The fresh gorgonian was immediately 
frozen after collection and kept at −20 °C until processing. A voucher specimen (WSG-5) was 
deposited in the School of Pharmacy, College of Medicine, National Taiwan University, Taipei. 
3.3. Extraction and Isolation 
The gorgonian J. fragilis (wet, 2.5 kg) was minced and extracted with acetone (3 × 5 L) at room 
temperature and the acetone extract was concentrated under vacuum. The crude extract (20 g) was 
partitioned between EtOAc and H2O (1:1). The EtOAc-soluble portion (15 g) was subjected to column 
chromatography using silica gel and eluted with a gradient of n-hexane/EtOAc (10:1 to 0:1) to obtain 
thirteen fractions (Fr.1~13). Fraction 6 (202 mg) was subjected to RP-HPLC using MeOH/H2O (60:40) 
to give 1 (3.9 mg) and 2 (1.8 mg). Fraction 9 (874 mg) was separated on silica gel column and eluted Mar. Drugs 2011, 9  
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with gradient n-hexane/EtOAc to give seven fractions (Fr. 9-1~6). Fr. 9-4 (157 mg) was purified by 
RP-HPLC, using solvent mixture of MeOH and H2O (65:35) to yield 4 (8.2 mg). Fr. 9-6 (211 mg) was 
separated on RP-HPLC using MeOH/H2O (60:40) to furnish 3 (4.5 mg). 
Frajunolide L (1): colorless amorphous gum; [α]
24
D +6.0 (c 0.2, CH2Cl2); IR νmax 3439, 2922, 2749, 
1768, 1735, 1370, 1248, 1221, 1040 cm
−1; 
1H NMR data (400 MHz, CDCl3), see Table 1;   
13C NMR data (100 MHz, CDCl3), see Table 2; ESIMS m/z 573 [M + Na]
+; HRESIMS m/z 573.2313 
[M + Na]
+ (calcd for C28H38O11Na, 573.2312). 
Frajunolide M (2): colorless amorphous powder; [α]
24
D +8.0 (c 0.2, CH2Cl2); IR νmax 3447, 2923, 
2853, 1773, 1735, 1645, 1375, 1240, 1223, 1041 cm
−1; 
1H NMR data (400 MHz, CDCl3), see Table 1; 
13C NMR data (100 MHz, CDCl3), see Table 2; ESIMS m/z 573 [M + Na]
+; HRESIMS m/z 573.2315 
[M + Na]
+ (calcd for C28H38O11Na, 573.2312). 
Frajunolide N (3): colorless amorphous powder; [α]
24
D +18.0 (c 0.1, CH2Cl2); IR νmax 3436, 2933, 
1780, 1735, 1376, 1255, 1235, 1212, 1044, 1017 cm
−1; 
1H NMR data (400 MHz, pyridine-d5), see 
Table 1; 
13C NMR data (100 MHz, pyridine-d5), see Table 2; ESIMS m/z 589 [M + Na]
+, 591   
[M + Na + 2]
+; HRESIMS m/z 589.2266 [M + Na]
+ (calcd for C28H38ClO12Na, 589.2261). 
Frajunolide O (4): colorless amorphous gum; [α]
24
D +6.7 (c 0.7, CH2Cl2); IR νmax 3467, 2927, 1780, 
1739, 1368, 1250, 1223, 1041 cm
−1; 
1H NMR data (400 MHz, pyridine-d5), see Table 1; 
13C NMR data 
(100 MHz, pyridine-d5), see Table 2; ESIMS m/z 607 [M]
+; HRESIMS m/z 607.1925   
[M + Na]
+ (calcd for C28H37ClO11Na, 607.1922), 609.1892 [M + Na + 2]
+. 
3.4. Human Neutrophils Superoxide Generation and Elastase Release 
Human neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. The 
assay of O2
•− generation was based on the SOD-inhibitable reduction of ferricytochrome c. 
Degranulation of azurophilic granules was determined by elastase release as described previously [16]. 
The elastase release experiments were performed using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as 
the elastase substrate. The fMet-Leu-Phe (fMLP), activated by Cytochalasin B (CB), was used as a 
stimulant. Genistein was used as a standard compound. 
4. Conclusion 
Chemical investigation of the Taiwanese gorgonian Junceella fragilis has resulted in the isolation of 
four new briarane diterpenoids, frajunolides L–O (1–4). Among them, compounds 1, 3 and 4 exhibited 
mild or selective anti-inflammatory activity. 
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